Unique ID issued by UMIN | UMIN000001571 |
---|---|
Receipt number | R000001894 |
Scientific Title | Postmastectomy chemoradiation therapy(weekly paclitaxel) after adjuvant or neoadjuvant chemothrapy in breast cancer : A phase 1 trial |
Date of disclosure of the study information | 2008/12/15 |
Last modified on | 2013/06/19 10:02:54 |
Postmastectomy chemoradiation therapy(weekly paclitaxel) after adjuvant or neoadjuvant chemothrapy in breast cancer : A phase 1 trial
Phase 1 trial of postmastectomy chemoradiation
Postmastectomy chemoradiation therapy(weekly paclitaxel) after adjuvant or neoadjuvant chemothrapy in breast cancer : A phase 1 trial
Phase 1 trial of postmastectomy chemoradiation
Japan |
breast cancer
Hematology and clinical oncology | Breast surgery | Radiology |
Malignancy
NO
To decide a maximum tolerated dose of weekly paclitaxel with concurrent radiation therapy
Safety
Confirmatory
Phase I
The decision of a maximum tolerated dose of weekly paclitaxel with concurrent radiation therapy
The decisin of a recommended dose of weekly paclitaxel with concurrent radiation therapy and confirmation of adverse reaction
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Weekly paclitaxel with concurrent radiation therapy
20 | years-old | <= |
75 | years-old | >= |
Female
The subjects of this study were the patients who were judged as meeting all the following conditions by investigators.
1)Histological doagnosis was breast cancer.
2)Age 20-75 years old
3)Underwent complete postomastectomy
4)>=4 positive axillary nodes,1-3 positive axillary nodes with or without tumor >5cm,positive axillary nodes before or after neoadjuvant chemotherapy,T4a or N3 and so someone required postomastectomy radiation therapy by attending physician
5)Having no major organ dysfunction
Neutrophils>=1500/mm3
Platelets>=100000/mm3
Hemoglobin>=9.0mg/dL
Creatinine<=1.5mg/dL
ALT,AST<=100IU/mL
Bilirubin<=1.5mg/dL
Physically normal ECG
Physically normal UCG
Chest Xp:lung field clear
6)Without serious complication and active second primary cancer
7)ECOG performance status 0-1
8)Having a life expectancy of >= 3 months
9)Provided written consent at the start of the study
This study excludes the patients who are judged as being contrary to every condition of the following conditions by investigators.
1)Severe pleural effusion,pleural effusion or ascites
2)Congestive heart failure, coronary insufficiency, acute myocardial infarction within 6 months
3)Cerebrovascular accident within 6 months
4)Poorly controlled diabetes or treated with insulin
5)Poorly controlled hypertension
6)Active infection
7)Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant after the study period
8)Psychological distress
9)Other patients judged as being inappropriate for the subjects of the study by attending physician
12
1st name | |
Middle name | |
Last name | Yuichi Ando |
Nagoya university hospital
Chemotherapeutics
65,tsurumai cho,shouwa ku,nagoya city
052-744-1902
1st name | |
Middle name | |
Last name | Sachi Morita |
Nagoya university hospital
Chemotherapeutics
052-744-1902
Nagoya university hospital
nothing
Self funding
NO
名古屋大学医学部附属病院
2008 | Year | 12 | Month | 15 | Day |
Unpublished
Completed
2008 | Year | 08 | Month | 18 | Day |
2009 | Year | 01 | Month | 01 | Day |
2013 | Year | 05 | Month | 30 | Day |
2013 | Year | 05 | Month | 30 | Day |
2013 | Year | 05 | Month | 30 | Day |
2013 | Year | 06 | Month | 30 | Day |
2008 | Year | 12 | Month | 12 | Day |
2013 | Year | 06 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001894
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |